<DOC>
	<DOCNO>NCT01225705</DOCNO>
	<brief_summary>Current European AIDS Clinical Society ( EACS ) guideline treatment HIV infection recommend combination antiretroviral regimen compose two nucleoside reverse transcriptase inhibitor plus ritonavir boost protease inhibitor non-nucleoside reverse transcriptase inhibitor . The non-nucleoside reverse transcriptase inhibitor license naïve patient - nevirapine efavirenz - asociated increased rate hepatotoxicity ( nevirapine ) CNS toxicity ( efavirenz ) HIV/HCV co-infected patient . Although PI-based therapy dramatically reduce morbidity mortality , limited complex dosing regimen toxicity , lead adherence challenge . Varying degree liver insufficiency may necessitate pharmacokinetic monitoring protease inhibitor may necessitate dose adjustment . In HIV/HCV co-infected patient HAART base another class antiretrovirals NNRTI PI may thus offer advantage regard adverse event thus long-term efficacy . The overall intention trial examine non-inferiority design safety efficacy raltegravir base HAART standard-of-care HAART HIV-/HCV co-infected patient . The standard care use study atazanavir/ritonavir . All patient addition receive fix combination tenofovir emtricitabine . The primary end-point rate hepatotoxic event , define ALT elevation .</brief_summary>
	<brief_title>Safety Study Raltegravir HIV/HCV Co-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV Hepatitis C coinfected patient indication HAART accord current GermanAustrian guideline HAART naive primary NRTI / Integrase / PI associate resistance mutation accord Stanford algorithm screening ; every patient MUST genotypic resistance assay prior baseline available ( &lt; 6 month prior baseline ) woman childbearing age : negative pregnancy test ability sign write informed consent advance liver cirrhosis ChildPugh B C decompensated liver disease Pegylated interferon / ribavirin antiHCV therapy ; plan antiHCV therapy duration study ( 48 week ) . acute chronic hepatitis B infection acute hepatitis A hepatotropic virus infection chronic liver disease alcohol abuse hemosiderosis use plan use ( duration study , 48 week ) rifampicin , St. John´s wort drug metabolize via cytochrome P450 system narrow therapeutic PKrange astemizole , terfenadine , cisapride , pimozide , chinidin , bepridil , triazolam , midazolam , ergotamine , dihydroergotamin , ergometrine , methylergometrine . FOR OTHER COMEDICATIONS please consult SPC Raltegravir ( Isentress® ) , Atazanavir ( Reyataz® ) , Ritonavir ( Norvir® ) , hospital pharmacist , www.hivdruginteractions.org principal investigator case uncertainty . new AIDS defining event , except Kaposi sarcoma , &lt; 1 month prior screen malignancy , except Kaposi sarcoma , current radio chemotherapy history organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>